J. Yaglom

Systematic Generation of Mutations at Topoisomerase II Cleavage Sites Enables Cancer Adaptation to Doxorubicin Therapy

It is shown that, in the subpopulation of cancer cells that survive initial Dox treatment, repair of Dox-induced DSBs leads to the accumulation of recurrent mutations at Top2 cleavage sites, effectively protecting the genome from Top2-mediated DNA damage and promoting the development of drug resistance.